ARCHIVES

Lilly drug Alimta misses the target, but wins ODAC endorsement for lung cancer. FDA’s Pazdur tells ODAC that decision on Alimta requires clinical judgment.

This article is from The Cancer Letter archive.

Vol. 30 No. 31 | July 30, 2004

Download PDF Visit The Full Archive

Related Articles

NCAB Approves CIS Recompetition, Restructuring

May 17, 1991

In Brief: NCAB Lacked Courage On Some Special Actions, Amos Says; Pick Reviewers On Ability Only, Scientist Asks

July 30, 1982

NCI Advisors: Resume Prevention Trial, Add Edometrial Sampling

May 13, 1994

Aventis, MediGene In Pact For Development Of Vaccine.

February 25, 2000

An Unlucky Streak? Doctors Analyze Errors As Another Cancer Center Offers Apology

June 30, 1995

President’s Cancer Panel Lists Recommendations For Improving Quality Of Cancer Care

April 9, 1999